CELGENE – ABRAXANE- A Phase III, randomized, open label, cross-over, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell non- small cell lung cancer (NSCLC)

A Phase III, randomized, open label, cross-over, multi-center, safety and efficacy study to evaluate nab-paclitaxel (Abraxane) as maintenance treatment after induction with nab-paclitaxel plus carboplatin in subjects with squamous cell non- small cell lung cancer (NSCLC)

CELGENE – ABRAXANE
Cancer
Mehul Patel, MD
Enrolling
Denise Maracle, RN
(585) 747-4555
(585) 922 - 9146